Group 1: Sales and Financial Goals - The financial data for Q4 2025 is still under audit, with specific sales figures to be disclosed in the annual report on April 23, 2026 [2] - The company aims to enhance both online and offline sales, leveraging R&D advantages and improving product offerings to boost profitability [2] Group 2: Product Structure and Development - The current product structure includes medical devices and functional skincare products, with various forms such as patches and non-patch products [3] - The company plans to introduce new products in 2026 across both categories, including dressings, masks, and various skincare formulations [3] Group 3: R&D and Innovation - The company employs a "North-South linkage + internal-external collaboration" R&D model, with dedicated centers in Shanghai and Harbin [3] - Collaboration with third-party research institutions is aimed at expanding research directions and enhancing R&D efficiency [3] Group 4: Sales Channel Optimization - The offline sales channel optimization is progressing as expected, focusing on transitioning to a value-driven sales model [4] - The strategy includes meticulous inventory management and dynamic price monitoring to prevent stockpiling risks [4] Group 5: Regulatory and Product Registration - In 2025, the company registered two new cosmetic ingredients: Feruloyl Tripeptide-129 Amide and Acetyl Dipeptide-110 Amide [4] - The company holds four Class II medical device registrations, including products like medical sodium hyaluronate repair patches [4] Group 6: Business Expansion and Investor Relations - The company is monitoring potential mergers and acquisitions but currently has no suitable targets [6] - The dividend plan for 2025 is yet to be determined, depending on the company's performance and funding plans for 2026 [6]
敷尔佳(301371) - 2026年3月3日投资者关系活动记录表